Home
Patient portrayal
Think it solvable.
Cerenome connects precision diagnostics, targeted therapeutics, and patient data into an integrated central nervous system (CNS) oncology platform designed to improve how CNS cancers are detected, treated, and understood.
How we’re changing CNS cancer care.
CNS cancers demand more than isolated innovations. They require a connected approach that improves how disease is detected, treated, and understood over time. That’s why we’re building an integrated platform that unites precision diagnostics, targeted therapeutics, and clinical data into one system, where every capability strengthens the others.
By bringing diagnostics, therapeutics, and clinical data together, each patient encounter strengthens future diagnosis, treatment, and research.
Diagnostics
Precision diagnostics, powered by CNSide®, detects, characterizes, and monitors CNS cancer from cerebrospinal fluid.
Therapeutics
REYOBIQ™ leads a portfolio of targeted radiotherapeutics being designed to deliver where conventional therapies often cannot.
Data Insights
Clinical data and AI help to generate insights that improve future patient care.
Diagnostics
Diagnostics strengthen therapeutics, sharpening who gets treated and how.
Therapeutics
Therapeutics strengthen diagnostics, built to change outcomes in diseases where progress has remained difficult for decades.
Data Insights
Data closes the loop, continuously strengthening every capability it touches.
Diagnostics
Based on capabilities already in clinical use, our diagnostics reflect years of focused work on CNS cancer.
Therapeutics
Ongoing clinical trials and peer-reviewed publications validate the approach.
Data Insights
Hundreds of evaluated patients form the foundation that brings every capability together as one system.
The next era of CNS oncology solutions.
Cerenome represents the evolution of work that began at Plus Therapeutics in 2020. Over those years, our focus sharpened into a conviction: CNS cancers present interconnected clinical challenges that require an integrated approach.
Today, as Cerenome, we carry that conviction forward. The same science, the same team, now built around a single integrated approach: diagnostics, therapeutics, and data, advancing together. Cerenome represents the next stage in our evolution—from individual technologies to a fully integrated CNS oncology platform.
This is the next chapter of that work.
Integrated CNS oncology platform.
Integrating precision diagnostics, targeted therapeutics, and clinical intelligence to improve outcomes for patients with CNS cancers.
CNSide®
Stage: Commercial
Stage: Launching soon
REYOBIQ™
(ReSPECT™ Clinical Trials)
Stage: Phase 2
Stage: Phase 2
Stage: Phase 1
Stage: Launching soon
- Change
- +0.04 (+1.04%)
- Volume
- —
- 52-Week High
- $4.16
- 52-Week Low
- $3.33
August 7, 2026 9:32 AM CDT
Minimum 15 minutes delayed. Source: LSEG